vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $143.3M, roughly 1.3× Piedmont Realty Trust, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 0.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 0.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
AXSM vs PDM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $143.3M |
| Net Profit | — | $-45.0M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | -31.4% |
| Revenue YoY | 57.4% | 0.4% |
| Net Profit YoY | — | -27.9% |
| EPS (diluted) | — | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $143.3M | ||
| Q4 25 | $196.0M | $142.9M | ||
| Q3 25 | $171.0M | $139.2M | ||
| Q2 25 | $150.0M | $140.3M | ||
| Q1 25 | $121.5M | $142.7M | ||
| Q4 24 | $118.8M | $143.2M | ||
| Q3 24 | $104.8M | $139.3M | ||
| Q2 24 | $87.2M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $-28.6M | $-43.2M | ||
| Q3 25 | $-47.2M | $-13.5M | ||
| Q2 25 | $-48.0M | $-16.8M | ||
| Q1 25 | $-59.4M | $-10.1M | ||
| Q4 24 | $-74.9M | $-30.0M | ||
| Q3 24 | $-64.6M | $-11.5M | ||
| Q2 24 | $-79.3M | $-9.8M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | -14.6% | -30.3% | ||
| Q3 25 | -27.6% | -9.7% | ||
| Q2 25 | -32.0% | -12.0% | ||
| Q1 25 | -48.9% | -7.1% | ||
| Q4 24 | -63.1% | -20.9% | ||
| Q3 24 | -61.7% | -8.3% | ||
| Q2 24 | -91.0% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $-0.55 | $-0.34 | ||
| Q3 25 | $-0.94 | $-0.11 | ||
| Q2 25 | $-0.97 | $-0.14 | ||
| Q1 25 | $-1.22 | $-0.08 | ||
| Q4 24 | $-1.54 | $-0.25 | ||
| Q3 24 | $-1.34 | $-0.09 | ||
| Q2 24 | $-1.67 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $2.3M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $1.5B |
| Total Assets | $713.6M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $2.3M | ||
| Q4 25 | $322.9M | $731.0K | ||
| Q3 25 | $325.3M | $3.0M | ||
| Q2 25 | $303.0M | $3.3M | ||
| Q1 25 | $300.9M | $2.9M | ||
| Q4 24 | $315.4M | $109.6M | ||
| Q3 24 | $327.3M | $133.6M | ||
| Q2 24 | $315.7M | $138.5M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $88.3M | $1.5B | ||
| Q3 25 | $73.7M | $1.5B | ||
| Q2 25 | $73.1M | $1.5B | ||
| Q1 25 | $53.2M | $1.6B | ||
| Q4 24 | $57.0M | $1.6B | ||
| Q3 24 | $92.9M | $1.6B | ||
| Q2 24 | $102.9M | $1.7B |
| Q1 26 | $713.6M | $4.0B | ||
| Q4 25 | $689.8M | $4.0B | ||
| Q3 25 | $669.3M | $4.0B | ||
| Q2 25 | $639.8M | $4.0B | ||
| Q1 25 | $596.7M | $4.0B | ||
| Q4 24 | $568.5M | $4.1B | ||
| Q3 24 | $561.5M | $4.1B | ||
| Q2 24 | $548.2M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
PDM
Segment breakdown not available.
